Infiltration of IL-17/IL-17A-secreting cells is associated with poor prognosis in BC patients [51–53], enhancing tumor migration, invasion, and chemotherapy resistance [54, 55]; the IL-17B/IL-17 B receptor (IL-17RB) axis is associated with poor prognosis and chemoresistance [56, 57], through the NF-κB/Bcl-2 antiapoptotic signaling pathway [58], becoming an attractive therapeutic target [59]. Here, IL17RB is linked to neoplasm.